Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.40 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.31 |
| ▸ | KDM5A | P29375 | 1/20 | 0.30 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.30 |
| ▸ | KIF11 | P52732 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21334960 | 0.74 | MAPK1 (0.38) | MAPK1DYRK1AKDM5AKDM5B | |
| SCHEMBL22792809 | 0.74 | DYRK1A (0.38) | MAPK1DYRK1A | |
| SCHEMBL1473042 | 0.74 | MAPK1 (0.45) | MAPK1DYRK1AIRAK4 | |
| SCHEMBL30167002 | 0.74 | MAPK1 (0.45) | MAPK1DYRK1AIRAK4 | |
| SCHEMBL9379898 | 0.73 | DYRK1A (0.41) | MAPK1DYRK1A | |
| SCHEMBL26661980 | 0.72 | HTT (0.37) | — | |
| SCHEMBL23920271 | 0.70 | DYRK1A (0.31) | DYRK1A | |
| SCHEMBL21335020 | 0.70 | MAPK1 (0.38) | MAPK1DYRK1A | |
| SCHEMBL2628882 | 0.69 | MAPK1 (0.45) | MAPK1DYRK1A | |
| SCHEMBL24348992 | 0.69 | MAPK1 (0.45) | MAPK1DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11820766-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-21 | — | — | US | disclosed |
| US-20230339900-A1 | CASEIN KINASE 1 DELTA MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2023-10-26 | — | — | US | disclosed |
| US-20230339970-A1 | CASEIN KINASE 1 DELTA MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2023-10-26 | — | — | US | disclosed |
| US-20230322721-A1 | TRIAZOLE DERIVATIVES AND THEIR USE AS TANKYRASE INHIBITORS | UNIVERSITY OF OULU (FI) | 2023-10-12 | — | — | US | disclosed |
| US-20230128198-A1 | NOVEL HETEROCYCLIC COMPOUNDS USEFUL AS AURORA A SELECTIVE INHIBITORS | JACOBIO PHARMACEUTICALS CO., LTD (CN) | 2023-04-27 | — | — | US | disclosed |
| US-20230128198-A1 | NOVEL HETEROCYCLIC COMPOUNDS USEFUL AS AURORA A SELECTIVE INHIBITORS | JACOBIO PHARMACEUTICALS CO., LTD (CN) | 2023-04-27 | — | — | US | disclosed |
| US-11384066-B1 | Heterocyclic compounds useful as aurora a selective inhibitors | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2022-07-12 | — | — | US | disclosed |
| US-11208411-B2 | Compositions and methods for treating parasitic diseases | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-12-28 | — | — | US | disclosed |
| WO-2021147974-A1 | NOVEL HETEROCYCLIC COMPOUNDS USEFUL AS AURORA A SELECTIVE INHIBITORS | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2021-07-29 | — | — | WO | disclosed |
| US-20200291030-A1 | COMPOSITIONS AND METHODS FOR TREATING PARASITIC DISEASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2020-09-17 | — | — | US | disclosed |
| US-20200062776-A1 | HEDGEHOG ACYLTRANSFERASE INHIBITORS AND USES THEREOF | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2020-02-27 | — | — | US | disclosed |
| US-10246469-B2 | Biaryl kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-04-02 | — | — | US | disclosed |
| US-20190040080-A1 | BIARYL KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2019-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190040080-A1 | BIARYL KINASE INHIBITORS | AAK1, CAMKK1, CAMKK2 | MAPK1 385/4885DYRK1A 382/4885IRAK4 701/4885 |
| US-20230339900-A1 | CASEIN KINASE 1 DELTA MODULATORS | CSNK1D, CSNK1A1, CSNK2A1 | MAPK1 234/4885DYRK1A 311/4885IRAK4 596/4885 |
| US-11384066-B1 | Heterocyclic compounds useful as aurora a selective inhibitors | AURKA, AURKC, AURKB | MAPK1 809/4885DYRK1A 1164/4885IRAK4 2639/4885 |
| US-10246469-B2 | Biaryl kinase inhibitors | AAK1, CAMKK1, CAMKK2 | MAPK1 385/4885DYRK1A 382/4885IRAK4 701/4885 |
| US-20230322721-A1 | TRIAZOLE DERIVATIVES AND THEIR USE AS TANKYRASE INHIBITORS | CBR3, GBA3, TECR | MAPK1 1823/4885DYRK1A 815/4885IRAK4 4021/4885 |
| US-20200291030-A1 | COMPOSITIONS AND METHODS FOR TREATING PARASITIC DISEASES | LIPA, LSS, LIPC | MAPK1 4788/4885DYRK1A 3323/4885IRAK4 2988/4885 |
| US-20230339970-A1 | CASEIN KINASE 1 DELTA MODULATORS | CSNK1D, CSNK1A1, CSNK1G1 | MAPK1 253/4885DYRK1A 543/4885IRAK4 598/4885 |
| US-11208411-B2 | Compositions and methods for treating parasitic diseases | LIPA, LSS, LIPC | MAPK1 4788/4885DYRK1A 3323/4885IRAK4 2988/4885 |
| US-20230128198-A1 | NOVEL HETEROCYCLIC COMPOUNDS USEFUL AS AURORA A SELECTIVE INHIBITORS | AURKA, AURKC, AURKB | MAPK1 585/4885DYRK1A 899/4885IRAK4 2048/4885 |
| US-20200062776-A1 | HEDGEHOG ACYLTRANSFERASE INHIBITORS AND USES THEREOF | HHAT, SHH, MBOAT1 | MAPK1 1398/4885DYRK1A 4777/4885IRAK4 3260/4885 |
| US-11820766-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, PNLIP | MAPK1 4389/4885DYRK1A 2576/4885IRAK4 1827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.